Jakbic Tablet contains Tofacitinib 5mg, a Janus kinase (JAK) inhibitor indicated for the treatment of various autoimmune conditions. Tofacitinib modulates the immune response by selectively inhibiting JAK enzymes, which play a critical role in the signaling pathways involved in inflammation and immune cell function. Jakbic is primarily prescribed for moderate to severe rheumatoid arthritis in patients who have had an inadequate response or intolerance to methotrexate. It is also approved for use in psoriatic arthritis and ulcerative colitis, providing symptomatic relief and improving physical function. The recommended dose is 5mg administered orally twice daily, with adjustments based on clinical response and tolerability. Patients receiving Jakbic should be monitored regularly for potential adverse effects, including infections, cytopenias, and lipid abnormalities, as Tofacitinib may increase susceptibility to serious infections such as tuberculosis and herpes zoster. Liver function tests and complete blood counts are advised prior to and during treatment. Jakbic is contraindicated in patients with active infections or known hypersensitivity to Tofacitinib. Caution is warranted in patients with a history of malignancy or cardiovascular risk factors. This medication should be used under strict medical supervision to optimize therapeutic outcomes and minimize risks.